Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs

M Elle Saine, Dena M Carbonari, Craig W Newcomb, Melissa S Nezamzadeh, Kevin Haynes, Jason A Roy, Serena Cardillo, Sean Hennessy, Crystal N Holick, Daina B Esposito, Arlene M Gallagher, Harshvinder Bhullar, Brian L Strom, Vincent Lo Re 3rd, M Elle Saine, Dena M Carbonari, Craig W Newcomb, Melissa S Nezamzadeh, Kevin Haynes, Jason A Roy, Serena Cardillo, Sean Hennessy, Crystal N Holick, Daina B Esposito, Arlene M Gallagher, Harshvinder Bhullar, Brian L Strom, Vincent Lo Re 3rd

Abstract

Background: The patterns and determinants of saxagliptin use among patients with type 2 diabetes mellitus (T2DM) are unknown in real-world settings. We compared the characteristics of T2DM patients who were new initiators of saxagliptin to those who were new initiators of non-dipeptidyl peptidase-4 (DPP-4) inhibitor oral anti-diabetic drugs (OADs) and identified factors associated with saxagliptin use.

Methods: We conducted a cross-sectional study within the Clinical Practice Research Datalink (CPRD), The Health Improvement Network (THIN), US Medicare, and the HealthCore Integrated Research Database (HIRD(SM)) across the first 36 months of saxagliptin availability (29 months for US Medicare). Patients were included if they were: 1) ≥18 years old, 2) newly prescribed saxagliptin or a non-DPP-4 inhibitor OAD, and 3) enrolled in their respective database for 180 days. For each saxagliptin initiator, we randomly selected up to ten non-DPP-4 inhibitor OAD initiators matched on age, sex, and geographic region. Conditional logistic regression was used to identify determinants of saxagliptin use.

Results: We identified 64,079 saxagliptin initiators (CPRD: 1,962; THIN: 2,084; US Medicare: 51,976; HIRD(SM): 8,057) and 610,660 non-DPP-4 inhibitor OAD initiators (CPRD: 19,484; THIN: 19,936; US Medicare: 493,432; HIRD(SM): 77,808). Across all four data sources, prior OAD use, hypertension, and hyperlipidemia were associated with saxagliptin use. Saxagliptin initiation was also associated with hemoglobin A1c results >8% within the UK data sources, and a greater number of hemoglobin A1c measurements in the US data sources.

Conclusions: In these UK and US data sources, initiation of saxagliptin was associated with prior poor glycemic control, prior OAD use, and diagnoses of hypertension and hyperlipidemia.

Trial registration: ClinicalTrials.gov identifiers NCT01086280 , NCT01086293 , NCT01086319 , NCT01086306 , and NCT01377935.

Figures

Figure 1
Figure 1
Selection of saxagliptin patients. a: Clinical Practice Research Datalink (CPRD). b: The Health Improvement Network (THIN). c: US Medicare. d: HealthCore Integrated Research DatabaseSM (HIRDSM).

References

    1. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet. 2011;378:31–40. doi: 10.1016/S0140-6736(11)60679-X.
    1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–53. doi: 10.2337/diacare.27.5.1047.
    1. Gonzalez EL, Johansson S, Wallander MA, Rodriguez LA. Trends in the prevalence and incidence of diabetes in the UK: 1996–2005. J Epidemiol Community Health. 2009;63:332–6. doi: 10.1136/jech.2008.080382.
    1. Centers for Disease Control and Prevention . National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014. Atlanta, GA: U.S. Department for Health and Human Services; 2014.
    1. Huang ES, Basu A, O’Grady M, Capretta JC. Projecting the future diabetes population size and related costs for the U.S. Diabetes Care. 2009;32:2225–9. doi: 10.2337/dc09-0459.
    1. Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulos S, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med. 2007;147:386–99. doi: 10.7326/0003-4819-147-6-200709180-00178.
    1. Tahrani AA, Piya MK, Barnett AH. Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Adv Ther. 2009;26:249–62. doi: 10.1007/s12325-009-0014-9.
    1. Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab. 2008;10:376–86. doi: 10.1111/j.1463-1326.2008.00876.x.
    1. Jadzinsky M, Pfutzner A, Paz-Pacheco E, Xu Z, Allen E, Chen R. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab. 2009;11:611–22. doi: 10.1111/j.1463-1326.2009.01056.x.
    1. DeFronzo RA, Hissa MN, Garber AJ, Luiz Gross J, Yuyan Duan R, Ravichandran S, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care. 2009;32:1649–55. doi: 10.2337/dc08-1984.
    1. Chacra AR, Tan GH, Apanovitch A, Ravichandran S, List J, Chen R. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract. 2009;63:1395–406. doi: 10.1111/j.1742-1241.2009.02143.x.
    1. Hollander P, Li J, Allen E, Chen R, Investigators C. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab. 2009;94:4810–9. doi: 10.1210/jc.2009-0550.
    1. Barnett AH, Charbonnel B, Donovan M, Fleming D, Chen R. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. Curr Med Res Opin. 2012;28:513–23. doi: 10.1185/03007995.2012.665046.
    1. SC Pradhan DGS, CH Shashindran, JS Bapna. Drug utilization studies. Natl Med J India 1988, 1:185–189.
    1. Khan GH, Aqil M, Pillai KK, Ahmad MA, Kapur P, Ain MR, et al. Therapeutic adherence: a prospective drug utilization study of oral hypoglycemic in patients with type 2 diabetes mellitus. Asian Pac J Trop Dis. 2014;4(Supplement 1):S347–52. doi: 10.1016/S2222-1808(14)60469-2.
    1. Walker AM. Confounding by indication. Epidemiology. 1996;7:335–6.
    1. Glynn RJ, Schneeweiss S, Stürmer T. Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol. 2006;98:253–9. doi: 10.1111/j.1742-7843.2006.pto_293.x.
    1. Lo Re V, 3rd, Haynes K, Ming EE, Wood Ives J, Horne LN, Fortier K, et al. Safety of saxagliptin: rationale for and design of a series of postmarketing observational studies. Pharmacoepidemiol Drug Saf. 2012;21(11):202–15. doi: 10.1002/pds.3318.
    1. Williams T, van Staa T, Puri S, Eaton S. Recent advances in the utility and use of the General Practice Research Database as an example of a UK Primary Care Data resource. Ther Adv Drug Saf. 2012;3:89–99. doi: 10.1177/2042098611435911.
    1. Horsfall LJ, Nazareth I, Petersen I. Serum uric acid and the risk of respiratory disease: a population-based cohort study. Thorax. 2014;69:1021–6. doi: 10.1136/thoraxjnl-2014-205271.
    1. Fett N, Haynes K, Propert KJ, Margolis DJ. Five-year malignancy incidence in patients with chronic pruritus: a population-based cohort study aimed at limiting unnecessary screening practices. J Am Acad Dermatol. 2014;70:651–8. doi: 10.1016/j.jaad.2013.11.045.
    1. Lewis JD, Schinnar R, Bilker WB, Wang X, Strom BL. Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf. 2007;16:393–401. doi: 10.1002/pds.1335.
    1. Lo Re V, 3rd, Haynes K, Forde KA, Localio AR, Schinnar R, Lewis JD. Validity of The Health Improvement Network (THIN) for epidemiologic studies of hepatitis C virus infection. Pharmacoepidemiol Drug Saf. 2009;18:807–14. doi: 10.1002/pds.1784.
    1. Cai B, Xu W, Bortnichak E, Watson DJ. An algorithm to identify medical practices common to both the General Practice Research Database and The Health Improvement Network database. Pharmacoepidemiol Drug Saf. 2012;21:770–4. doi: 10.1002/pds.3277.
    1. Chan KA, Truman A, Gurwitz JH, Hurley JS, Martinson B, Platt R, et al. A cohort study of the incidence of serious acute liver injury in diabetic patients treated with hypoglycemic agents. Arch Intern Med. 2003;163:728–34. doi: 10.1001/archinte.163.6.728.
    1. Bullano MF, McNeeley BJ, Yu YF, Quimbo R, Burawski LP, Yu EB, et al. Comparison of costs associated with the use of etanercept, infliximab, and adalimumab for the treatment of rheumatoid arthritis. Manag Care Interface. 2006;19:47–53.
    1. Sarawate C, Sikirica MV, Willey VJ, Bullano MF, Hauch O. Monitoring anticoagulation in atrial fibrillation. J Thromb Thrombolysis. 2006;21:191–8. doi: 10.1007/s11239-006-4968-z.
    1. Kamat SA, Gandhi SK, Davidson M. Comparative effectiveness of rosuvastatin versus other statin therapies in patients at increased risk of failure to achieve low-density lipoprotein goals. Curr Med Res Opin. 2007;23:1121–30. doi: 10.1185/030079907X182167.
    1. Young BA, Lin E, Von Korff M, Simon G, Ciechanowski P, Ludman EJ, et al. Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization. Am J Manag Care. 2008;14:15–23.
    1. American Diabetes Association Standards of medical care in diabetes-2014. Diabetes Care. 2014;37(Supplement 1):S14–S280. doi: 10.2337/dc14-S014.
    1. Mamdani M, Sykora K, Li P, Normand S-LT, Streiner DL, Austin PC, et al. Reader’s guide to critical appraisal of cohort studies: 2. Assessing potential for confounding. BMJ: British Medical Journal. 2005;330:960–2. doi: 10.1136/bmj.330.7497.960.
    1. Lee D, Bergman U. Studies of Drug Utilization. Pharmacoepidemiology. Fifth edn. Oxford, UK: John Wiley & Sons, Ltd.; 2012.
    1. Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin. 2009;25:1019–27. doi: 10.1185/03007990902820519.
    1. Cai B, Katz L, Alexander CM, Williams-Herman D, Girman CJ. Characteristics of patients prescribed sitagliptin and other oral antihyperglycaemic agents in a large US claims database. Int J Clin Pract. 2010;64:1601–8. doi: 10.1111/j.1742-1241.2010.02516.x.
    1. Brodovicz KG, Kou TD, Alexander CM, O’Neill EA, Senderak M, Engel SS, et al. Recent trends in the characteristics of patients prescribed sitagliptin and other oral antihyperglycaemic agents in a large U.S. claims database. Int J Clin Pract. 2013;67:449–54. doi: 10.1111/ijcp.12090.
    1. Zhang Q, Rajagopalan S, Mavros P, Engel SS, Davies MJ, Yin D, et al. Baseline characteristic differences between patients prescribed sitagliptin vs. other oral antihyperglycemic agents: analysis of a US electronic medical record database. Curr Med Res Opin. 2010;26:1697–703. doi: 10.1185/03007995.2010.489029.
    1. Zhang Q, Rajagopalan S, Mavros P, Engel SS, Davies MJ, Yin D, et al. Differences in baseline characteristics between patients prescribed sitagliptin versus exenatide based on a US electronic medical record database. Adv Ther. 2010;27:223–32. doi: 10.1007/s12325-010-0024-7.
    1. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care. 2012;35:1364–79. doi: 10.2337/dc12-0413.
    1. Hampp C, Borders-Hemphill V, Moeny DG, Wysowski DK. Use of antidiabetic drugs in the U.S., 2003–2012. Diabetes Care. 2014;37:1367–74. doi: 10.2337/dc13-2289.
    1. Flory JH, Hennessy S. Metformin Use Reduction in Mild to Moderate Renal Impairment: Possible Inappropriate Curbing of Use Based on Food and Drug Administration Contraindicaitons. JAMA Intern Med. 2014.
    1. Sulkin TV, Bosman D, Krentz AJ. Contraindications to metformin therapy in patients with NIDDM. Diabetes Care. 1997;20:925–8. doi: 10.2337/diacare.20.6.925.
    1. Calabrese AT, Coley KC, DaPos SV, Swanson D, Rao RH. Evaluation of prescribing practices: risk of lactic acidosis with metformin therapy. Arch Intern Med. 2002;162:434–7. doi: 10.1001/archinte.162.4.434.
    1. Kennedy L, Herman WH. Renal status among patients using metformin in a primary care setting. Diabetes Care. 2005;28:922–4. doi: 10.2337/diacare.28.4.922.
    1. Vasisht KP, Chen SC, Peng Y, Bakris GL. Limitations of metformin use in patients with kidney disease: are they warranted? Diabetes Obes Metab. 2010;12:1079–83. doi: 10.1111/j.1463-1326.2010.01295.x.
    1. Horlen C, Malone R, Bryant B, Dennis B, Carey T, Pignone M, et al. Frequency of inappropriate metformin prescriptions. JAMA. 2002;287:2504–5. doi: 10.1001/jama.287.19.2504-a.
    1. Bloomgarden ZT, Dodis R, Viscoli CM, Holmboe ES, Inzucchi SE. Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis. Diabetes Care. 2006;29:2137–9. doi: 10.2337/dc06-1120.
    1. Chapell R, Gould AL, Alexander CM. Baseline differences in A1C explain apparent differences in efficacy of sitagliptin, rosiglitazone and pioglitazone. Diabetes Obes Metab. 2009;11:1009–16. doi: 10.1111/j.1463-1326.2009.01084.x.
    1. Hall GC, Sauer B, Bourke A, Brown JS, Reynolds MW, Casale RL. Guidelines for good database selection and use in pharmacoepidemiology research. Pharmacoepidemiol Drug Saf. 2012;21:1–10. doi: 10.1002/pds.2229.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa